Three Studies Presented at 43rd EASL Strongly Indicate Better Efficacy for PEGASYS in Curing Hepatitis C
Geschrieben am 26-04-2008 |
Basel, Switzerland (ots/PRNewswire) -
- Roche Also Provides Comment on Results of "IDEAL" Trial
Roche today announced that compelling new data from three studies indicate that chronic hepatitis C patients who received PEGASYS(R) (peginterferon alfa-2a) plus COPEGUS(R) (ribavirin) had a greater chance of being cured of their disease than those who received combination therapy with another pegylated interferon and ribavirin. Results from the studies were presented this week at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) in Milan, Italy.
Ascione, et al: A Prospective, Randomised, Investigator-Initiated Head-to-Head Trial
Results of this independently-conducted study(1) were presented by Professor Antonio Ascione, Director of the Department of Gastroenterology Liver Unit at Cardarelli Hospital in Naples, Italy, in the oral late-breaker session at EASL. It is a prospective, randomised, investigator-initiated head-to-head trial designed to directly compare Pegasys with peginterferon alfa-2b, each in combination with ribavirin. Enrolling 320 patients in Italy, the study randomised patients to receive either Pegasys 180 mcg/week or peginterferon alfa-2b 1.5 mcg/kg/week. Importantly, patients received equivalent starting doses of ribavirin (either 1,000 or 1,200 mg ribavirin per day based on body weight), and the process for ribavirin dose reduction was the same for all patients.
The results showed that 68.7% of patients on Pegasys achieved a cure, compared to only 54.4% of patients on peginterferon alfa-2b (p=0.008). Furthermore, in genotypes 1 and 4 - the most difficult-to-treat patient group - Pegasys achieved a cure in 54.8% of patients, compared to only 39.8% on peginterferon alfa-2b (p=0.04). Side effects were similar, although there were more withdrawals for side effects in the peginterferon alfa-2b group.
T. Witthoeft, et al: Hepatitis C Treatment in Real-Life PRACTICE in Germany
Another study presented at EASL, called PRACTICE, analysed the response of 3,470 patients to hepatitis C treatment between 2000 and 2007 in 23 German treatment centres with a high volume of patients(2). Patients were matched by key baseline characteristics, as well as by those who received a similar cumulative ribavirin dose. Among these matched pairs, significantly more patients treated with Pegasys plus Copegus achieved a cure compared to those treated with peginterferon alfa-2b and ribavirin (59.3% vs. 53.0% (p = 0.008)).
Craxi, et al: PROBE Compares the Pegylated Interferons
PROBE, an observational study, was designed to prospectively evaluate the efficacy of the pegylated interferons in real-life practice(3). The study enrolled 1,351 patients with genotype 1 virus at 167 treatment centres in Italy. Again, the trial found a greater chance of a cure in patients treated with Pegasys combination therapy compared to those treated with peginterferon alfa-2b combination therapy (41% versus 34%, respectively (p=0.004)).
"We are pleased that three separate studies presented at EASL all indicate that Pegasys provided patients with a better chance for a cure. These results will help physicians and patients make an informed choice of treatment for chronic hepatitis C. In fact, in all the major markets, an increasing proportion of physicians and patients have selected Pegasys for their therapy in the last several months," said Dr Ueli Fankhauser, global leader for Pegasys at Roche. "We are committed to further advancing the treatment of hepatitis C. Reflecting Roche's leadership in this area, our comprehensive clinical trials programme aims to optimise treatment with Pegasys and Copegus in the hope of bringing treatment success to even more patients."
Roche Comments on Schering-Plough "IDEAL" Study
Roche reiterated its position on the Schering-Plough sponsored trial called "IDEAL," results of which were also presented at EASL. Clear biases(4) in the design of this study prevent any direct comparison of the pegylated interferons. These biases include:
- different blinding for the Pegasys arm,
- different ribavirin starting doses,
- a different ribavirin dose reduction protocol, and
- unequal thresholds for the use of erythropoietin-stimulating agents.
Despite these biases, it is interesting to note that significantly more patients in the Pegasys arm had an undetectable viral load while on treatment ("end of treatment" response)(5). This is a promising finding, given that the likelihood for a cure in these patients is even higher when modern treatment principles, such as extending the treatment period beyond 48 weeks, are applied. In addition, the study failed to show a benefit for weight-based dosing of peginterferon alfa-2b (which requires dose adjustments based on a patient's body weight) vs. Pegasys, which is given as a fixed dose regardless of a patient's body weight.
About Hepatitis C
Hepatitis C (HCV), the most common chronic blood-borne infection, is transmitted primarily through blood or blood products. HCV chronically affects 180 million people worldwide, which makes it over four times more prevalent than HIV. It is a leading cause of cirrhosis, liver cancer and liver failure, despite the fact that many patients can be cured.
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totalled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion Swiss francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people. Additional information is available on the Internet at http://www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Film footage is available for broadcast journalists from The NewsMarket at http://www.thenewsmarket.com. Video is compressed in MPEG2 and is available for download to your FTP server.
References
1.Ascione A, Tartaqlione MT, Lampasi F, et al. Peginterferon Alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin in naïve patients ith chronic hepatitis C viris infection: results of a prospective randomised trial. In: 43rd Annual Meeting of the European Association for the Study of the Liver (EASL); 23-27 April 2008; ; 2008; Milan, Italy; 2008.
2.Witthoeft T, Hueppe D, John C, et al. Efficacy and safety of peginterferon alfa-2a or -2b plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Germany: the practice study. In: 43rd Annual Meeting of the European Association for the Study of the Liver (EASL); 23-27 April 2008; 2008; Milan, Italy; 2008.
3.Craxi A, Piccinino F, Alberti A, et al. Predictors of SVR in naïve HCV G1 patients in real life practice: the probe. In: 43rd Annual Meeting of the European Association for the Study of the Liver (EASL); 23-27 April 2008; 2008; Milan, Italy; 2008.
4.McHutchinson J and Sulkowski M. Scientific Rationale and study design of the individualised dosing efficacy vs. flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing with genotype 1 chronic hepatitis C. Journal of Viral Hepatitis. doi:10.1111/j.1365-2893.2008.00973.x
5.Schering-Plough Reports Top-Line Results of the IDEAL Study. Schering-Plough News Release, 2008. (Accessed April 16, 2008, at http ://www.schering-plough.com/schering_plough/news/release.jsp?releaseID =1096126.)
ots Originaltext: Roche Pharmaceuticals Im Internet recherchierbar: http://www.presseportal.de
Contact: Contact: Mike Nelson, Roche, +41(79)572-5165, Michelle Marchione, Axon Communications, +44 (0) 208 439 9449
Kontaktinformationen:
Leider liegen uns zu diesem Artikel keine separaten Kontaktinformationen gespeichert vor.
Am Ende der Pressemitteilung finden Sie meist die Kontaktdaten des Verfassers.
Neu! Bewerten Sie unsere Artikel in der rechten Navigationsleiste und finden
Sie außerdem den meist aufgerufenen Artikel in dieser Rubrik.
Sie suche nach weiteren Pressenachrichten?
Mehr zu diesem Thema finden Sie auf folgender Übersichtsseite. Desweiteren finden Sie dort auch Nachrichten aus anderen Genres.
http://www.bankkaufmann.com/topics.html
Weitere Informationen erhalten Sie per E-Mail unter der Adresse: info@bankkaufmann.com.
@-symbol Internet Media UG (haftungsbeschränkt)
Schulstr. 18
D-91245 Simmelsdorf
E-Mail: media(at)at-symbol.de
133492
weitere Artikel:
- BVR: Importierte Inflation erfordert Lohndisziplin Berlin (ots) - Der aktuelle Anstieg der Inflationsrate ist überwiegend auf außenwirtschaftliche Faktoren zurückzuführen. Dieser Erkenntnis müssen die Tarifpartner in der laufenden Lohnrunde Rechnung tragen, so der Bundesverband der Deutschen Volksbanken und Raiffeisenbanken (BVR) in seinem jüngsten Konjunkturbericht. Für importierte Inflation könne es keine Lohnkompensation geben. Orientierungsgröße für die Tarifparteien könne daher lediglich die Kernrate der Inflation, das heißt, die um die Energie- und Nahrungsmittelpreise bereinigte mehr...
- Der Tagesspiegel: Roland-Berger-Chef fordert Abschaffung kurzfristiger Boni für Top-Manager Berlin (ots) - Die am kurzfristigen Erfolg orientierte Vergütung von Top-Managern muss nach Ansicht von Burkhard Schwenker, Chef der zweitgrößten deutschen Unternehmensberatung Roland Berger, abgeschafft werden. "Boni, die nur den Erfolg eines Jahr messen, müssen bei vielen Geschäften mit langfristigen Auswirkungen versagen", sagte Schwenker dem "Tagesspiegel" (Montagausgabe) mit Blick auf die anhaltende Finanzkrise. Die Absicht der Finanzbranche, über ihre Vergütungssysteme diskutieren zu wollen, begrüßte er. "Wenn man die Krise jetzt mehr...
- Der Tagesspiegel: Grüne: Bahnprivatisierung hat katastrophale Folgen Berlin (ots) - Winfried Hermann, verkehrspolitischer Sprecher von Bündnis 90/Die Grünen, lehnt die geplante Teilprivatisierung der Deutschen Bahn als "Ausverkauf des Schienenverkehrs" ab. In einem Beitrag für den Berliner Tagesspiegel (Montagausgabe), schreibt Hermann weiter, "die geplante Privatisierung ist intransparent und trägt paradoxe Züge: Da werden unter dem Dach einer Staatsholding zwei Holding-Tochtergesellschaften gebildet. Die eine ist für die Infrastruktur verantwortlich und dem Gemeinwohl verpflichtet; die andere, teilprivatisierte mehr...
- WAZ: HVB erweist sich Bärendienst - Kommentar von Daniel Freudenreich Essen (ots) - Die HypoVereinsbank "mistet aus": Das Geldhaus will Kunden, die es einst mit Kampfkonditionen angelockt hat, wohl wie lästigen Ballast entsorgen. Das "Vergehen" der Kreditnehmer: Nach Spiegel-Recherchen wollten sie nur eine HVB-Finanzierung haben und brachten nicht genug Gewinn in die Bank-Kasse. Das Signal, das die Bank mit dem Reinemachen an ihre Kunden ausschickt, ist verheerend. Frei nach dem Motto: Gestern wart ihr noch gut genug, heute brauchen wir euch nicht mehr. Das Gegenteil ist der Fall: Eine Bank lebt nicht mehr...
- LVZ: SPD-Wirtschaftsexperte Wend: Vorschläge zur Senkung der Energiepreise an Populismus nicht zu überbieten Leipzig (ots) - In der Debatte um staatliche Eingriffe zur Senkung der Energiepreise hat der wirtschaftspolitische Sprecher der SPD-Bundestagsfraktion, Rainer Wend, scharfe Kritik an den zum Wochenende gemachten Vorschlägen geübt. "Sie sind an Populismus nicht mehr zu überbieten. Eine solche Politik verachte ich", sagte der Sozialdemokrat der Leipziger Volkszeitung (Montagausgabe). Eine Entlastung durch einen reduzierten Mehrwertsteuersatz, wie es FDP-Parteichef Guido Westerwelle fordert, so Wend weiter, würde nur dazu führen, dass die mehr...
|
|
|
Mehr zu dem Thema Aktuelle Wirtschaftsnews
Der meistgelesene Artikel zu dem Thema:
DBV löst Berechtigungsscheine von knapp 344 Mio. EUR ein
durchschnittliche Punktzahl: 0 Stimmen: 0
|